Inquiry Basket
Loading ......
Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a transformative treatment modality for hematological malignancies, with CD19-targeted products demonstrating remarkable clinical success against B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and mantle cell lymphoma. The majority of clinically approved CD19 CAR-T therapies employ the FMC63-derived single-chain variable fragment (scFv) as their antigen-recognition domain. FMC63 is a murine anti-CD19 monoclonal antibody whose scFv combines the variable heavy and variable light chain domains through a flexible peptide linker, conferring high specificity for the CD19 ectodomain while maintaining compatibility with diverse CAR signaling architectures. As CAR-T products advance from clinical trials into routine therapeutic use, comprehensive bioanalytical characterization of the CAR construct components becomes essential. The measurement of free FMC63 scFv, total FMC63 scFv (encompassing both free and target-bound forms), and host anti-FMC63 antibodies provides complementary pharmacokinetic, pharmacodynamic, and immunogenicity information. Free FMC63 reflects unbound circulating CAR construct or shed scFv levels; total FMC63 captures the full exposure profile including CAR-T cell surface-bound and target-complexed moieties; and anti-FMC63 antibody detection enables immunogenicity risk assessment. The Free FMC63 ELISA Kit, Total FMC63 ELISA Kit, and Anti-FMC63 ELISA Kit constitute an integrated analytical portfolio designed to support the full lifecycle of FMC63-based CAR-T research and development.
Figure 1.Comprehensive ELISA Solutions for FMC63-Based CD19 CAR-T Research.
| Key Molecular Targets | Details |
| CD19 Antigen Recognition | CD19 is a transmembrane glycoprotein belonging to the immunoglobulin superfamily, expressed from early pre-B-cell stages through mature B lymphocytes and downregulated only upon terminal plasma cell differentiation. In FMC63-based CAR-T constructs, the scFv engages an epitope within the CD19 ectodomain with high binding affinity, enabling selective recognition of CD19-positive malignant and normal B cells while sparing CD19-negative tissues. The Free FMC63 ELISA Kit monitors unbound scFv that has not engaged this target antigen. |
| CAR-T Cell Signaling and Effector Activation | Upon CD19 engagement, the FMC63 scFv transmits activation signals through the CAR intracellular domain. This engagement triggers cytolytic degranulation, perforin/granzyme-mediated apoptosis, and pro-inflammatory cytokine release against CD19-positive cells. The Total FMC63 ELISA Kit measures the cumulative exposure of all FMC63-containing species, providing a pharmacodynamic correlate of CAR-T engagement and target-mediated disposition. |
| Anti-Drug Antibody Immunogenicity Pathway | The murine origin of FMC63 introduces the risk of human anti-mouse antibody responses, which can evolve into anti-FMC63 antibodies with neutralizing or non-neutralizing activity. Neutralizing antibodies may occlude the CD19-binding paratope, impair CAR-T cytolytic function, and accelerate clearance of the CAR construct, while binding antibodies can form immune complexes that alter pharmacokinetics or elicit hypersensitivity reactions. The Anti-FMC63 ELISA Kit enables qualitative surveillance of these humoral responses, supporting immunogenicity risk stratification during clinical development. |
The immunogenicity of FMC63-based CAR-T therapy originates primarily from the xenogeneic nature of the murine scFv, which contains framework and complementarity-determining region sequences that may be recognized as foreign by the human immune system. Following CAR-T infusion, residual free FMC63 scFv—whether shed from the cell surface, released during CAR-T apoptosis, or present in manufacturing residuals—can be internalized by antigen-presenting cells. Intracellular proteolysis generates peptide fragments that are loaded onto MHC class II molecules and presented to CD4+ T follicular helper cells, which in turn provide co-stimulatory signals to B cells bearing FMC63-specific B-cell receptors.
Affinity maturation within germinal centers yields plasma cells secreting anti-FMC63 IgG antibodies. These antibodies can be classified based on functional impact: binding antibodies that recognize FMC63 without necessarily blocking CD19 engagement, and neutralizing antibodies that directly interfere with the antigen-binding site. The Anti-FMC63 ELISA Kit detects the presence of these antibodies through a solid-phase sandwich assay, using FMC63-coated plates and HRP-conjugated probes with results evaluated against a validated cutoff value. Concurrent use of the Free FMC63 and Total FMC63 kits enables investigators to distinguish between free analyte depletion due to target binding versus accelerated clearance driven by anti-FMC63 antibody-mediated elimination.
The Free FMC63 ELISA Kit, Total FMC63 ELISA Kit, and Anti-FMC63 ELISA Kit collectively address multiple bioanalytical requirements across the CAR-T development continuum, with targeted application values as follows:
| Applications | Details |
| Pharmacokinetic Profiling and Exposure Assessment | The Free FMC63 ELISA Kit quantifies unbound scFv in serum and plasma, supporting the calculation of free-drug pharmacokinetic parameters. The Total FMC63 ELISA Kit complements this by capturing the full analyte pool, enabling total exposure modeling and target-mediated drug disposition analysis. Together, these assays provide a mechanistic understanding of FMC63 pharmacokinetics in preclinical models and clinical subjects. |
| CAR-T Pharmacodynamics and Biodistribution Studies | By comparing free versus total FMC63 levels in peripheral blood, bone marrow, lymphoid tissue, and tumor microenvironment samples, researchers can infer CAR-T engagement, antigen sink effects, and tissue distribution patterns. Persistent elevation of total FMC63 relative to free FMC63 may indicate sustained CAR-T presence at target-rich sites, while rapid decline of both species may signal CAR-T contraction or immune-mediated clearance. |
| Immunogenicity Monitoring and Humanization Strategies | The Anti-FMC63 ELISA Kit enables routine screening for anti-scFv antibodies in clinical trial cohorts, facilitating correlation between immunogenicity incidence and clinical outcomes such as cytokine release syndrome severity, treatment response, and relapse kinetics. These data inform the rational design of humanized or affinity-optimized FMC63 variants that preserve potent CD19 recognition while minimizing immunogenicity risk in repeat-dosing or outpatient CAR-T regimens. |
This quantitative sandwich ELISA kit is designed for the specific detection of free FMC63 scFv in human serum and plasma specimens. The assay utilizes an FMC63-coated microplate, an HRP-conjugated detection probe, and TMB chromogenic substrate to generate a signal proportional to free FMC63 concentration. With reliable intra- and inter-assay precision, this product serves as a dependable tool for free-form analyte monitoring, shedding studies, and pharmacokinetic characterization of FMC63-containing CAR-T products.
The Total FMC63 ELISA Kit provides quantitative measurement of the complete FMC63 pool, including free scFv, target-bound scFv, and immune-complexed species. This comprehensive detection capability is essential for total exposure assessment and target-mediated disposition modeling in CAR-T pharmacokinetic studies. The assay shares the same sandwich-format architecture and precision specifications as the free kit, ensuring methodological consistency when both assays are deployed in parallel.
This qualitative immunoassay enables detection of host anti-FMC63 antibodies in human serum and plasma, supporting immunogenicity surveillance for FMC63-based CAR-T therapies. The kit employs an FMC63-coated microplate and HRP-conjugated probe with results interpreted using a validated cutoff threshold. It is indispensable for clinical immunogenicity assessment, biosimilar comparability studies, and the development of next-generation low-immunogenicity CD19 CAR constructs.
FMC63 remains the dominant scFv backbone for clinically approved CD19-directed CAR-T therapies, underpinned by its well-characterized CD19 recognition profile and robust effector activation potential. However, the successful translation and long-term utilization of FMC63-based products demand rigorous bioanalytical characterization across three interconnected dimensions: free scFv exposure, total scFv exposure, and host anti-scFv immunogenicity. The Free FMC63 ELISA Kit delivers focused quantification of circulating unbound analyte, the Total FMC63 ELISA Kit captures the complete exposure profile including target-complexed species, and the Anti-FMC63 ELISA Kit enables qualitative detection of humoral immune responses.
When applied as an integrated analytical system, these three kits provide researchers and clinicians with the data necessary to optimize CAR-T dosing regimens, interpret pharmacokinetic-pharmacodynamic relationships, evaluate immunogenicity risk, and guide the engineering of improved CD19-targeting modalities. The combined use of free, total, and anti-FMC63 assays establishes a comprehensive bioanalytical framework that supports the full lifecycle of FMC63-directed CAR-T biotherapeutics from preclinical discovery through post-marketing surveillance.
| Cat. No. | Product Name | Species Reactivity | Application | Detection Method | BusinessCode | RefAuthor | Size | |
| DEIA-JY25016 | Free FMC63 ELISA Kit | Human | Quantitative | ELISA | CD-E-O | 96T | Inquiry | |
| DEIA-JY25036 | Total FMC63 ELISA Kit | Human | Quantitative | ELISA | CD-E-O | 96T | Inquiry | |
| DEIA-JY25054 | Anti-FMC63 ELISA Kit | Human | Qualitative | ELISA | CD-E-O | 96T | Inquiry |
Loading ......
